#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.